The physiological structure, function and distribution of cytoskeletal proteins and their abnormal expression are closely related to the development of neurological and renal diseases. With in-depth knowledge of cytoskeleton-related fields and extensive project experience, CD BioSciences provides reference materials on motor neuron disease to help you learn more about our various testing services and welcome you to contact us directly for more specific solutions.
Mechanisms of Motor Neuron Disease
Motor neuron disease (MND) is one of the most progressive and physically changing of the adult neurodegenerative disorders. Weakness of the limbs and medullary muscle tissue leads to increased dependence on activities of daily living, and patients usually die from the complications of chronic respiratory failure. Traditionally, MND has been defined by a relatively selective loss of upper motor neurons from the corticospinal tract and a variable loss of lower motor neurons from the brainstem nuclei and anterior horn cells of the spinal cord. This classic combination syndrome of muscle atrophy secondary to lower motor neuron loss, combined with sclerosis of the lateral corticospinal tract, is known as amyotrophic lateral sclerosis (ALS).
The spectrum of motor neuron diseases [1].
Effect of MND-related Genes on Cytoskeleton Dynamics
Amyotrophic lateral sclerosis (ALS) is a motor neuron disease characterized by the progressive loss of motor neurons (MN) in the cerebral cortex, brainstem, and spinal cord. As the MN degenerates, synaptic connections to its target muscles are lost, resulting in muscle spasticity, weakness, and atrophy. Disruption of cytoskeletal integrity and MT-dependent transport mechanisms may translate into the inability of MNs to provide essential components for their synapses and/or to transmit information back to the cell body, potentially triggering a degenerative process. Recently, several genes known to play a role in cytoskeletal dynamics have been associated with ALS: alsin rho guanine nucleotide exchange factor (ALS2), kinesin subunit 1 (DCTN1), kinesin family member 5A (KIF5A), neurofilament light (NF-L), heavy neurofilament (NF-H), peripheral protein (PRPH), profilin 1 (PFN1), spastin (SPAST) and microtubulin alpha 4a (TUBA4A).
Proteins are encoded by amyotrophic lateral sclerosis (ALS)-related genes affecting cytoskeletal dynamics [1].
Our Services
Motor neuron disease is a serious group of neurodegenerative diseases, also known as acromegaly, for which there is no cure. CD BioSciences offer the most comprehensive services for motor neuron disease programs. Through rigorous monitoring and effective execution, we are committed to providing the most valuable solutions to complete your research project.
- Motor Neuron Disease Model Construction
We offer gene editing mouse models of various cytoskeleton-related genes in MND, including DCTN1, TUBA4A, NF-L, etc., to help our customers conduct research related to this disease.
- Cytoskeletal Antibody Development for Motor Neuron Disease
We develop and produce antibodies related to MND genes, including superoxide dismutase 1 (SOD1) and TDP-43, which are widely available to scholars and clients in various fields to accelerate the development of therapies for Parkinson's disease patients.
- Cytoskeletal Compounds Screening for Motor Neuron Disease
We have a well-established compound screening process and an extensive compound library to help our clients conduct disease-related research by providing compound screening services for MND-related proteins.
Our Advantages
Advanced Biotechnology
Customizable Designs
Competitive Pricing
Best After-sales Service
CD BioSciences provides our global customers with cost effective, high quality and efficient research solutions for cytoskeleton related diseases. We guarantee on-time delivery of our products and results, please contact us for more details.
References
- Jenkins T M, et al. Imaging muscle as a potential biomarker of denervation in motor neuron disease[J]. Journal of Neurology, Neurosurgery & Psychiatry, 2018, 89(3): 248-255.
- Statland J M, et al. Patterns of weakness, classification of motor neuron disease, and clinical diagnosis of sporadic amyotrophic lateral sclerosis[J]. Neurologic clinics, 2015, 33(4): 735-748.
For research use only. Not intended for any clinical use.
